Shopping Cart
- Remove All
Your shopping cart is currently empty
Anti-VEGFR2/KDR Antibody-FITC (1T318)
😃Good
Catalog No. TMAY-00061F
Alias VEGFR2, VEGFR, kinase insert domain receptor, FLK1, CD309
Anti-VEGFR2/KDR Antibody-FITC (1T318) is a FITC-conjugated Mouse antibody targeting VEGFR2/KDR. Anti-VEGFR2/KDR Antibody-FITC (1T318) can be used in FCM.
Anti-VEGFR2/KDR Antibody-FITC (1T318)
Anti-VEGFR2/KDR Antibody-FITC (1T318)
😃Good
Catalog No. TMAY-00061FAlias VEGFR2, VEGFR, kinase insert domain receptor, FLK1, CD309
Anti-VEGFR2/KDR Antibody-FITC (1T318) is a FITC-conjugated Mouse antibody targeting VEGFR2/KDR. Anti-VEGFR2/KDR Antibody-FITC (1T318) can be used in FCM.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 T | $104 | 7-10 days | |
| 100 T | $328 | 7-10 days |
Bulk & Custom
Add to Cart
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
| Description | Antibody Type: Mouse Monoclonal Application: FCM Reactivity: Human |
| Alias | VEGFR2, VEGFR, kinase insert domain receptor, FLK1, CD309 |
| Ig Type | Mouse IgG1 |
| Clone | 1T318 |
| Reactivity | Human |
| Verified Activity | Flow cytometric analysis of Human VEGFR2(CD309) expression on HUVEC cells. Cells were stained with FITC-conjugated anti-Human VEGFR2(CD309). The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
| Application | FCM |
| Recommended Dose | 10 μl/Test, 0.1 mg/ml |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human VEGFR2/KDR/Flk-1/CD309 (rh VEGFR2/KDR/Flk-1/CD309; TMPY-02361; NP_002244.1; Met1-Glu764) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | PBS solution containing 0.5% BSA and 0.09% sodium azide |
| Research Background | VEGFR2 also called KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling are critical to endothelial cell survival, maintenance of the vasculature and alveolar structure, and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
| Conjucates | FITC |
| Others Formats | Unconjugated/APC/PE |
| Antibody Types Available | 4 |
| Immunogen | Recombinant Protein: Human VEGFR2/KDR/Flk-1/CD309 Protein (TMPY-02361) |
| Antigen Species | Human |
| Biology Area | Cancer Drug Targets, Hemangioblast Markers, Receptor Tyrosine Kinases (RTKs) |
Stability & Storage
| Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal. |
| Transport | Shipping with blue ice. |
Sci Citations
Calculator
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . 
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Anti-VEGFR2/KDR Antibody-FITC (1T318) | purchase Anti-VEGFR2/KDR Antibody-FITC (1T318) | Anti-VEGFR2/KDR Antibody-FITC (1T318) cost | order Anti-VEGFR2/KDR Antibody-FITC (1T318)
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.